SHARI REITZEN-BASTIDAS, M.D.
Facial Plastic Surgery Physician in NEW YORK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: SHARI REITZEN-BASTIDAS, M.D. reported a CMS MIPS final score of 84.0144 out of 100, above the 83.1 national average, and filed 142 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
SHARI REITZEN-BASTIDAS, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
SHARI REITZEN-BASTIDAS, M.D. at a glance
Near national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Facial Plastic Surgery Physician compares to other specialties among New York providers
Facial Plastic Surgery Physician share within New York
Facial Plastic Surgery Physician is one of the more visible NUCC categories in New York
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
SHARI REITZEN-BASTIDAS, M.D.'s 2023 MIPS final score plotted against the Facial Plastic Surgery Physician national average
- MIPS Final Score
- 84.0144/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Facial Plastic Surgery Physician) — 84.0144/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Facial Plastic Surgery Physician US NPIs
84.0144/100 MIPS final score — 0.9 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Facial Plastic Surgery Physician. Quality dim: 68.6752. Cost dim: 76.4864.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
SHARI REITZEN-BASTIDAS, M.D. is a Facial Plastic Surgery Physician provider practicing in NEW YORK, New York, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1225173370. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
SHARI REITZEN-BASTIDAS, M.D. appears in the CMS NPPES registry as a Facial Plastic Surgery Physician provider holding M.D. credentials at 715 PARK AVE STE 2, NEW YORK, NY, 10021, with a listed phone of (347) 557-8368. NPI 1225173370 was issued on 02/20/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what REITZEN-BASTIDAS most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 142 prescription claims written by this provider, covering 48 Medicare beneficiaries and totaling roughly $12K in drug spend, split 19% brand-name and 81% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 84.0144/100 for the 2023 performance year (Quality 68.6752, Cost 76.4864), compared with the national average of 83.1.
Facial Plastic Surgery Physician is a narrow specialty nationwide, with 607 enrolled providers across 47 states and an average of 428 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1225173370 |
|---|---|
| Specialty | Facial Plastic Surgery Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 02/20/2007 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm SHARI REITZEN-BASTIDAS, M.D.'s current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for SHARI REITZEN-BASTIDAS, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$21
Largest payer
Optinose US, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to SHARI REITZEN-BASTIDAS, M.D.. To verify SHARI REITZEN-BASTIDAS, M.D.'s current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
19% brand-name claims vs 81% generic, on 142 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 196
- Total Day Supply
- 4,953
- Brand vs Generic
- 19% brand / 81% generic
- Brand Drug Cost
- $9K
- Generic Drug Cost
- $3K
- Antibiotic Claims
- 24
Patient Demographics
- Average Patient Age
- 71.4 years
- Avg HCC Risk Score
- 0.96
- Gender Split
- 54% female / 46% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Fluticasone Propionate | 33 |
| Ipratropium Bromide | 23 |
| Xhance Fluticasone Propionate | 12 |
| Azelastine Hcl | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Facial Plastic Surgery Physician Overview
How SHARI REITZEN-BASTIDAS, M.D. fits within the Facial Plastic Surgery Physician landscape nationally.
SHARI REITZEN-BASTIDAS, M.D.'s 142 claims are below the specialty average of 428.
Nearby Facial Plastic Surgery Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as REITZEN-BASTIDAS.
Compare Facial Plastic Surgery Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is SHARI REITZEN-BASTIDAS, M.D.'s specialty? ▼
How much does SHARI REITZEN-BASTIDAS, M.D. prescribe under Medicare Part D? ▼
What is SHARI REITZEN-BASTIDAS, M.D.'s Medicare quality score? ▼
Where is SHARI REITZEN-BASTIDAS, M.D. located? ▼
What is SHARI REITZEN-BASTIDAS, M.D.'s NPI number? ▼
Does SHARI REITZEN-BASTIDAS, M.D. prescribe more brand-name or generic drugs? ▼
How many Facial Plastic Surgery Physician providers are there in the US? ▼
What drugs does SHARI REITZEN-BASTIDAS, M.D. prescribe most often? ▼
Does SHARI REITZEN-BASTIDAS, M.D. accept Medicare? ▼
How can I verify SHARI REITZEN-BASTIDAS, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology